Literature DB >> 24449212

Immune evasion by oncogenic proteins of acute myeloid leukemia.

Shlomo Elias1, Rachel Yamin, Lior Golomb, Pinchas Tsukerman, Noah Stanietsky-Kaynan, Dina Ben-Yehuda, Ofer Mandelboim.   

Abstract

PML-RARA and AML1-ETO are important oncogenic fusion proteins that play a central role in transformation to acute myeloid leukemia (AML). Whether these fusion proteins render the tumor cells with immune evasion properties is unknown. Here we show that both oncogenic proteins specifically downregulate the expression of CD48, a ligand of the natural killer (NK) cell activating receptor 2B4, thereby leading to decreased killing by NK cells. We demonstrate that this process is histone deacetylase (HDAC)-dependent, that it is mediated through the downregulation of CD48 messenger RNA, and that treatment with HDAC inhibitors (HDACi) restores the expression of CD48. Furthermore, by using chromatin immunoprecepitation (ChIP) experiments, we show that AML1-ETO directly interacts with CD48. Finally, we show that AML patients who are carrying these specific translocations have low expression of CD48.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24449212      PMCID: PMC3981677          DOI: 10.1182/blood-2013-09-526590

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  61 in total

Review 1.  Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia.

Authors:  A Melnick; J D Licht
Journal:  Blood       Date:  1999-05-15       Impact factor: 22.113

2.  Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt.

Authors:  P Erickson; J Gao; K S Chang; T Look; E Whisenant; S Raimondi; R Lasher; J Trujillo; J Rowley; H Drabkin
Journal:  Blood       Date:  1992-10-01       Impact factor: 22.113

Review 3.  Natural killer cell immune escape in acute myeloid leukemia.

Authors:  E Lion; Y Willemen; Z N Berneman; V F I Van Tendeloo; E L J Smits
Journal:  Leukemia       Date:  2012-03-26       Impact factor: 11.528

4.  Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells.

Authors:  O Mandelboim; N Lieberman; M Lev; L Paul; T I Arnon; Y Bushkin; D M Davis; J L Strominger; J W Yewdell; A Porgador
Journal:  Nature       Date:  2001-02-22       Impact factor: 49.962

5.  Addiction of t(8;21) and inv(16) acute myeloid leukemia to native RUNX1.

Authors:  Oren Ben-Ami; Dan Friedman; Dena Leshkowitz; Dalia Goldenberg; Kira Orlovsky; Niv Pencovich; Joseph Lotem; Amos Tanay; Yoram Groner
Journal:  Cell Rep       Date:  2013-09-19       Impact factor: 9.423

6.  PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia.

Authors:  Joost H A Martens; Arie B Brinkman; Femke Simmer; Kees-Jan Francoijs; Angela Nebbioso; Felicetto Ferrara; Lucia Altucci; Hendrik G Stunnenberg
Journal:  Cancer Cell       Date:  2010-02-17       Impact factor: 31.743

7.  Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia.

Authors:  F Tajima; T Kawatani; A Endo; H Kawasaki
Journal:  Leukemia       Date:  1996-03       Impact factor: 11.528

Review 8.  Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Authors:  Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

9.  ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia.

Authors:  Joost H A Martens; Amit Mandoli; Femke Simmer; Bart-Jan Wierenga; Sadia Saeed; Abhishek A Singh; Lucia Altucci; Edo Vellenga; Hendrik G Stunnenberg
Journal:  Blood       Date:  2012-09-14       Impact factor: 22.113

10.  Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity.

Authors:  A Pessino; S Sivori; C Bottino; A Malaspina; L Morelli; L Moretta; R Biassoni; A Moretta
Journal:  J Exp Med       Date:  1998-09-07       Impact factor: 14.307

View more
  20 in total

1.  Signaling Lymphocytic Activation Molecule Family Receptor Homologs in New World Monkey Cytomegaloviruses.

Authors:  Natàlia Pérez-Carmona; Domènec Farré; Pablo Martínez-Vicente; Cox Terhorst; Pablo Engel; Ana Angulo
Journal:  J Virol       Date:  2015-09-02       Impact factor: 5.103

2.  KIR B or not to be?...that is the question for ALL.

Authors:  Michael R Verneris; Jeffrey S Miller
Journal:  Blood       Date:  2014-10-23       Impact factor: 22.113

Review 3.  Acute myeloid leukemia and NK cells: two warriors confront each other.

Authors:  Aroa Baragaño Raneros; Carlos López-Larrea; Beatriz Suárez-Álvarez
Journal:  Oncoimmunology       Date:  2018-10-31       Impact factor: 8.110

Review 4.  Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia.

Authors:  Hanna A Knaus; Christopher G Kanakry; Leo Luznik; Ivana Gojo
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

Review 5.  Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Authors:  Georgios Petros Barakos; Eleftheria Hatzimichael
Journal:  Diseases       Date:  2022-06-10

Review 6.  Roles of CD48 in regulating immunity and tolerance.

Authors:  Shannon L McArdel; Cox Terhorst; Arlene H Sharpe
Journal:  Clin Immunol       Date:  2016-01-18       Impact factor: 3.969

Review 7.  Immune escape and immunotherapy of acute myeloid leukemia.

Authors:  Luca Vago; Ivana Gojo
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 8.  Targeting transcription factors in cancer - from undruggable to reality.

Authors:  John H Bushweller
Journal:  Nat Rev Cancer       Date:  2019-09-11       Impact factor: 60.716

9.  Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia.

Authors:  Lin Fu; Jinlong Shi; Kai Hu; Jijun Wang; Weidong Wang; Xiaoyan Ke
Journal:  Oncotarget       Date:  2015-04-10

10.  Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack.

Authors:  Chamutal Gur; Yara Ibrahim; Batya Isaacson; Rachel Yamin; Jawad Abed; Moriya Gamliel; Jonatan Enk; Yotam Bar-On; Noah Stanietsky-Kaynan; Shunit Coppenhagen-Glazer; Noam Shussman; Gideon Almogy; Angelica Cuapio; Erhard Hofer; Dror Mevorach; Adi Tabib; Rona Ortenberg; Gal Markel; Karmela Miklić; Stipan Jonjic; Caitlin A Brennan; Wendy S Garrett; Gilad Bachrach; Ofer Mandelboim
Journal:  Immunity       Date:  2015-02-10       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.